ABSTRACT. The auditory brainstem response (ABR) was monitored during infusion of bilirubin in six ventilated newborn rhesus monkeys (138-145 d gestation) while acute changes in pH were produced by varying inspired C02. Prolonged respiratory acidosis without bilirubin infusion produced minimal changes in the ABR (one animal). C 0 2 exposure, usually initiated when the bilirubin level reached -20 mg/dL, decreased arterial pH to values ranging from 6.85 to 7.10. ABR changes, including prolongation of the wave 11-IV peak to peak intervals and decreased wave amplitudes, first developed 2-4 h after initial exposure to C01. Total and unbound bilirubin levels at this time ranged from 376 to 564 pmol/L (22-33 mg/dL) and 38 to 65 nmol/ L (2.5-3.8 pg/dL), respectively. Correction of respiratory acidosis produced partial to complete reversal of ABR changes within 3 to 20 min. Reexposure to C 0 2 immediately reproduced the ABR abnormality. Production and reversal of the abnormal ABR was obtained through two to three cycles in three animals. Thus, when the brainstem bilirubin level was near the threshold for toxicity, the effect of changes in Pco2 on the ABR were immediate, suggesting that auditory pathway toxicity is initially mediated by a reversible pH-dependent bilirubin-membrane complex. In contrast to humans, in monkeys auditory toxicity appeared to be a late manifestation of bilirubin toxicity, inasmuch as all monkeys were obtunded and apneic 30-70 min before ABR abnormalities appeared. Notwithstanding these limitations, the results support the hypothesis that bilirubin toxicity can be both promoted and reversed by modulating brain pH. (Pediatr Res 34: 6-9, 1993) 
Bilirubin is a dicarboxylic acid and is thought to exist primarily as the dianion in plasma (I). The nearly insoluble free bilirubin acid concentration increases with decreasing pH and with increasing total bilirubin concentration, creating a supersaturated unbound bilirubin level in hyperbilirubinemic infants (2, 3) . The uptake of bilirubin by tissue also increases with decreasing pH (4-9), whereas serum binding remains unchanged (9, lo), and Brodersen and coworkers (1-3) have proposed that bilirubin encephalopathy results from the deposition of insoluble bilirubin acid aggregates in or on susceptible neuronal membranes (1-3).
Although precipitation of bilirubin in membranes may represent the final stage of kernicterus (1 l), there is increasing evidence that early bilirubin toxicity and possibly the chain of events leading to lethal toxicity may be initiated by quite a different mechanism. It is unlikely that precipitation of a supersaturated bilirubin solution is responsible for changes in the ABR (1 2-1 8), because ABR abnormalities may be corrected during exchange transfusion even when the free bilirubin concentration remains above proposed levels of solubility (2, 12, 13) . Furthermore, we have found that nearly all binding of bilirubin to red blood cells or mitochondria is due to a reversible pH-dependent mechanism involving a single proton addition (4). This suggested to us that the soluble monovalent anion and not the insoluble bilirubin acid is responsible for initial partitioning between plasma and tissue.
These observations led us to postulate that early toxicity might involve reversible pH-dependent bilirubin-membrane complexes. If true, dissolution as well as formation of toxic complexes in brain should occur rapidly after a sudden change in brain pH and should be reflected in a measurable expression of neurotoxicity. To test this hypothesis, we examined the effects of pH jumps on brainstem function as measured by the ABR of jaundiced premature primates. We modified pH by C02 inhalation because C02 equilibrates rapidly across the blood-brain bamer, immediately altering cerebral pH. The premature newborn rhesus monkey was selected as an experimental model because it is born with an immature bilirubin processing system resulting in unconjugated hyperbilirubinemia (19) and has a threshold for developing bilirubin brainstem toxicity similar to that seen in human newborn infants (20) .
MATERIALS AND METHODS
Six newborn rhesus monkeys (Macaca mzilatra) were delivered by cesarean section at 138-145'd gestation. he monkeys were immediately intubated and stabilized using an Infant Star ventilator (Infrasonics Corp., San Diego, CA). Arterial lines were placed for sampling, blood pressure monitoring, and glucose infusion. Blood was replaced with heparinized placental blood and maternal blood. Venous lines were established in the inferior vena cava for bilirubin infusion. The animals were initially sedated with ketamine. Blood eases were modulated bv infusine fat-free human serum albumin (Sigma) to obtain a final bilirubin concentration of I mg/mL and a bi1irubin:albumin molar ratio of 20: 1. Bilirubin-albumin solutions were refreshed hourly, shielded from light, and infused through a 0.45-pm Millipore filter.
ABR recordings were made immediately after stabilizing the preparation and at 5-to 10-min intervals throughout the study using a Nicolet Compact IV electro-diagnostic system (Nicolet Biomedical Instruments, Madison, WI). Subcutaneous needle recording electrodes were placed over each mastoid and at the vertex. A ground electrode was placed on the forehead. Earphones (Nicolet, TDH-39) were placed 1 cm from the ear and produced clicks at 75 dB intensity relative to threshold in a group of adult humans with normal hearing. Masking noise of 45 dB intensity was given to the opposite ear. Responses to 2000 rarefaction click stimuli of 0.1 ms duration were averaged at a rate of 1 1.4/s, stored on disk, and displayed on hard copy. The latencies and amplitudes from baseline of waves I, 11, and IV were measured, and the I-IV and 11-IV peak to peak intervals were calculated for each response (2 1-23). In the monkey, wave I1 arises from the cochlear nucleus and wave IV is generated by the lateral lemniscus (23); therefore, the 11-IV peak to peak interval was used to measure brainstem conduction.
Total bilirubin levels were assayed by absorption at 460 nm, correcting for Hb. In five of six animals, unbound bilirubin levels were estimated using the peroxidase method (24) (UB Analyzer, Arrow Co., Osaka, Japan). Blood gases and electrolytes were monitored using a Nova Stat Profile 5 analyzer. Data were statistically analyzed using analysis of variance and paired t test. This research was approved by the animal use committee of the University of California, Davis, and conformed to NIH guidelines for the care and use of laboratory animals.
RESULTS
Bilirubin was initially infused at a rate of 25 mg/kg/h, producing serum bilirubin levels ranging from 273 to 376 pmol/L (16-22 mg/dL) by 1 h. The infusion rate was then slowed and C 0 2 was introduced, raising the Pco2 to 12.4-16.7 kPa (93-125 mm Hg) and decreasing arterial blood pH to 6.85-7.10. In one animal, CO2 was introduced 2.4 h before bilirubin infusion, producing a minimal pH of 6.89. This produced minimal changes in the ABR: a slight increase in wave I latency (2.60 to 2.84 ms) and an increase in wave IV amplitude (0.46 to 0.68 PV).
Initially, the animals responded to the elevated Pco2 with tachypnea and agitation, requiring ketamine sedation. After exposure to hyperbilirubinemia and hypercarbia for 1.5-2 h, the animals became depressed, with minimal response to stimulation and only reflex inspiration during positive pressure ventilation. Changes in the ABR first appeared 30-70 min after general neurologic depression was observed.
Maximum bilirubin levels during the procedure ranged from 410 to 564 pmol/L (24-33 mg/dL) and usually coincided with the onset of neurologic depression. Bilirubin levels ranged from 376 to 530 pmol/L (22-31 mg/dL) when ABR changes first appeared. At this time, unbound bilirubin levels ranged between 38 and 65 nmol/L (2.2-3.8 pg/dL). Serum binding deteriorated in most animals as signs of toxicity progressed, and the unbound bilirubin levels generally remained high despite a decrease in total serum bilirubin concentration.
ABR changes initially consisted of prolongation of 11-IV interval, followed by a decrease in amplitude in waves I1 or IV.
Wave I remained intact in five of six animals. When the amplitude in any wave form decreased 50% or more, C 0 2 infusion was discontinued and minute ventilation was increased. In all animals, there was immediate recovery in the ABR, with the ABR approaching baseline values within 10 min in three of six animals (Fig. 1, Table 1 ). Two monkeys had partial improvement and one animal had only transient improvement. The most t Represents 2nd change. This monkey was exposed to C02 for 2.4 h before adding bilirubin. Before C02 exposure, 11-IV interval was 2.20 ms, and IV amplitude was 0.46 pV. Wave IV amplitude increased to 0.68 with C02 exposure. When bilirubin reached 410 pmol/L, IV amplitude decreased to 0.29 pV and 11-IV decreased to 1.96 ms. Normalization of pH reduced 11-IV further to 1.72 ms, but IV amplitude remained unchanged. These values are used as baseline for this primate.
significant change in the ABR in response to pH manipulation was in the 11-IV peak to peak interval. Data from the first cycle in each of the six animals demonstrated that acidosis in the presence of hyperbilirubinemia prolonged the 11-IV interval from 2.13 + 0.17 ms (mean + SD) to 2.54 + 0.25 ms. With a return to a less acidotic pH, this interval recovered to 2.06 f 0.30 ms ( p = 0.008, F Z .~~ = 6.7 1) ( Table 2 ). The data were also analyzed by paired t test, because the large SD in baseline values might obscure changes when comparing group means. Significant differences between COz exposure and both baseline and recovery values were found in wave IV latency and both I-IV and 11-IV peak to peak intervals. t ANOVA, analysis of variance.
Reinstatement of C 0 2 immediately reproduced the ABR abnormalities in all animals. Production and complete or partial reversal of the ABR abnormalities were obtained through two cycles in two animals and three cycles in one animal before irreversible clinical deterioration (hypotension, metabolic acidosis) occurred. The severity of ABR changes usually increased with each C 0 2 exposure.
Oxygen requirements increased during the procedure. In one animal, reversal of the ABR abnormality occurred after increasing pH even with a Po2 value of 3.7 kPa (28 mm Hg). Elevation of the Pco2 produced an increase in blood pressure and a decrease in heart rate in all animals. Conversely, normalization of the Pco2 resulted in a decrease in blood pressure. Three animals became hypotensive when the Pco2 was reduced (mean arterial pressure 16-22 mm Hg), but this did not prevent improvement in the ABR.
DISCUSSION
We report herein evidence that modulation of brain Pc02 and presumably brain pH acutely alters the threshold of bilirubin , toxicity as measured by the ABR. When the tissue bilirubin level is near threshold for toxicity, the effect of changes in P C O~ on the ABR are immediate and dramatic, suggesting that auditory pathway toxicity is initially mediated by a reversible pH-dependent bilirubin-membrane complex. The change in the 11-IV peak to peak interval suggests thai bilirubin primarily affects central conduction rather than the peripheral component of the ABR (23) . Wave I, reflecting peripheral 8th nerve function, was attenuated in only one animal.
Several studies have previously demonstrated that hypercapnia will increase brain bilirubin content (25) (26) (27) (28) , and this has been attributed to either alteration of pH or increased cerebral blood flow (28, 29) . This study confirms previous suggestions that hypercarbia should increase bilirubin toxicity, but further demonstrates that reducing Pc02 can rapidly reverse bilirubin toxicity. This observation suggests that alteration of cerebral pH must play a more important role in the effect of hypercarbia on bilirubin toxicity, inasmuch as a decrease in cerebral blood flow with correction of hypercarbia would not be expected to rapidly remove bilirubin from brain. Although we hypothesized that increasing brain pH would reverse toxic bilirubin acid-membrane complexes, this study does not preclude the possibility that hypercarbia and bilirubin have independent but synergistic effects on brain function. In the absence of bilirubin, however, the ABR has been reported to be very resistant to hypoxic and hypercarbic conditions. Sohmer et al. (30) found a small but statistically significant increase in wave IV latency in cats under severe hypercarbic conditions (25% C02, pH 6.8-6.9) but no effect on wave amplitude. Hypoxia had no effect on the ABR, although either hypoxia or hypercapnia severely depressed EEG activity. In this study, only one animal received prolonged exposure to C02 with minimal changes in the ABR. CO2 effects would be expected to occur fairly acutely, and all animals were exposed to C 0 2 for 2 h or longer in the presence of bilirubin before an effect was observed. Thereafter, changes were immediate. The delay in the onset of ABR changes is more likely due to the slow equilibration of bilirubin between plasma and brain compartments than to a delayed response to hypercarbia.
In contrast to humans, in the premature primate auditory toxicity appeared to be a late manifestation of bilirubin toxicity, at least under the experimental conditions used. All monkeys were obtunded and apneic before ABR abnormalities appeared. These manifestations of bilirubin poisoning were not reversed by eliminating respiratory acidosis and may or may not be mediated by a pH-dependent mechanism.
These studies are too preliminary to recommend the use of hyperventilation in treating patients with hyperbilirubinemia and signs of bilirubin encephalopathy, but they do emphasize the need to be attentive to brain pH and particularly to arterial Pco2 in patients at risk for kernicterus. Newborns with respiratory disease and hypercarbia associated with hyperbilirubinemia might be expected to have lower thresholds for neurotoxicity. These findings suggest that evaluation and treatment of patients with severe hyperbilirubinemia would be enhanced by measuring the arterial blood gas and monitoring acid-base status. This may be particularly important in patients undergoing exchange transfusion.
